Related Experiment Video
Updated: Dec 23, 2025

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Allelic heterogeneity of Proteus syndrome
Anna Buser1, Marjorie J Lindhurst1, Hannah C Kondolf1
1Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, USA.
Insights
Proteus syndrome, a mosaic disorder, is now linked to a new AKT1 gene variant, p.(Glu17Arg). This discovery expands genetic testing recommendations for individuals with suspected Proteus syndrome.
Area of Science:
- Genetics
- Molecular Biology
- Pathology
Background:
- Proteus syndrome is a rare mosaic disorder characterized by progressive overgrowth.
- Previously, it was solely linked to the mosaic c.49G > A p.(Glu17Lys) variant in the AKT1 gene.
- This AKT1 variant is also implicated in various cancers.
Purpose of the Study:
- To identify the genetic cause in a severe Proteus syndrome case.
- To investigate potential allelic heterogeneity in Proteus syndrome.
- To expand diagnostic approaches for Proteus syndrome.
Main Methods:
- Genetic sequencing of the AKT1 gene in affected tissues.
- Analysis of variant allele fraction in patient-derived fibroblasts.
- Functional assays to assess AKT1 variant activity via AKT phosphorylation.
Main Results:
- A novel mosaic c.49_50delinsAG p.(Glu17Arg) variant in AKT1 was identified in the patient.
- This variant showed constitutive activation of AKT(S473).
- Variant allele fractions varied across different tissues.
Conclusions:
- This study documents allelic heterogeneity for Proteus syndrome.
- The findings suggest that other AKT1 variants can cause Proteus syndrome.
- Genetic testing for Proteus syndrome should include screening for additional AKT1 variants beyond p.(Glu17Lys).
Abstract:
Proteus syndrome is a mosaic disorder that can cause progressive postnatal overgrowth of nearly any organ or tissue. To date, Proteus syndrome has been exclusively associated with the mosaic c.49G > A p.(Glu17Lys) pathogenic variant in AKT1, a variant that is also present in many cancers. Here we describe an individual with severe Proteus syndrome who died at 7.5 yr of age from combined parenchymal and restrictive pulmonary disease. Remarkably, this individual was found to harbor a mosaic c.49_50delinsAG p.(Glu17Arg) variant in AKT1 at a variant allele fraction that ranged from <0.01 to 0.46 in fibroblasts established from an overgrown digit. This variant was demonstrated to be constitutively activating by phosphorylation of AKT(S473). These data document allelic heterogeneity for Proteus syndrome. We recommend that individuals with a potential clinical diagnosis of Proteus syndrome who are negative for the p.(Glu17Lys) variant be tested for other variants in AKT1.
Related Concept Videos
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Export of Misfolded Proteins out of the ER
Pleiotropy
Epistasis Analysis
Multiple Allele Traits

